

| カタログ番号 | HY286676 |
|---|---|
| 種反応性 | Human |
| アプリケーション | ELISA, Bioactivity: FCM, Functional assay, Research in vivo |
| 宿主種 | Human |
| クローン性 | Monoclonal |
| アイソタイプ | IgG |
| クローンID | H2Mab-139 |
| 生物学的活性 | H 2 Mab-139 (10 ug/mL; 30 min at 4°C) specifically binds to HER2 on LN229/HER2 glioblastoma cells and the colorectal cancer cell lines Caco-2, HCT-116, HCT-15, HT-29, LS 174T, COLO 201, COLO 205, HCT-8, SW1116, and DLD-1 in flow cytometry assays [1]. H2Mab-139 (10 ug/mL) specifically detects HER2 protein with a molecular weight of approximately 200 kDa in LN229/HER2 glioblastoma cell lysates via Western blotting [1]. H2Mab-139 (10 ug/mL; 1 h at room temperature) specifically stains the cell membrane of HER2-positive human colon cancer tissue sections in immunohistochemical assays [1]. H2Mab-19 (6 ng/mL to 100 ug/mL) maintains high binding affinity for HER2 in HER2-expressing BT-474, HSC-2, and SAS cell lines, with K d values of 2.3 × 10 -8 M, 9.5 × 10 -9 M, and 5.5 × 10 -9 M, respectively [2]. H2Mab-19 (5 h at 37°C) exhibits high CDC activity against BT-474, HSC-2 and SAS cell lines, with cytotoxicity rates of 46%, 51% and 53%, respectively [2]. H2Mab-19 (100 ug per dose; i.p.; on days 1, 7, and 14 after cell implantation) significantly reduces tumor development and tumor weight in BT-474 breast cancer xenografts [2]. H2Mab-19 (100 ug per dose; i.p.; on days 1, 6, and 14 after cell implantation) significantly reduces tumor development and tumor weight in HSC-2 oral cancer xenografts [2]. |
| ターゲット | CD340, EC:2.7.10.1, ERBB2, HER2, MLN 19, MLN19, Metastatic lymph node gene 19 protein, NEU, NGL, Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Receptor tyrosine-protein kinase erbB-2, Tyrosine kinase-type cell surface receptor HER2, p185erbB2 |
| エンドトキシンレベル | < 10 EU/mg |
| 純度 | >95% as determined by SDS-PAGE. |
| 精製 | Protein A/G purified from cell culture supernatant. |
| アクセッション番号 | P04626 |
| 形態 | Liquid |
| 保存バッファー | 0.01M PBS pH 7.4. データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。 |
| 安定性と保存 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| 別名 | H2Mab-139, H2Mab139, H2Mab139 |
| 背景 | Receptor tyrosine-protein kinase erbB-2 (CD340/ERBB2) is a ~137 kDa protein. Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. CD340 is the therapeutic target of trastuzumab (Herceptin) and trastuzumab deruxtecan (Enhertu). |
| 参考文献 | 1. Kaneko MK, et al. Development of an Anti-HER2 Monoclonal Antibody H2Mab-139 Against Colon Cancer. Monoclon Antib Immunodiagn Immunother. 2018;37(1):59-62. [HY286676] 2. Takei J, et al. H 2 Mab-19, an anti-human epidermal growth factor receptor 2 monoclonal antibody exerts antitumor activity in mouse oral cancer xenografts. Exp Ther Med. 2020;20(2):846-853. [HY286676] |
| 注意事項 | For research use only. Not suitable for clinical or therapeutic use. |

SDS-PAGE for Research Grade Anti-Human CD340/ERBB2/HER2/NEU (H2Mab-139)


+86-027-65523339
中国武漢市深敦寺路666号C棟、武漢、430206

中文
English
한국어
日本語
Español
Français
Русский